Clinical Trials in Denver

Showing 10921-10940 of 15,604 trials

Vascular Inflammation in Psoriasis - Extension Study

NCT01866592

VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E extends VIP study procedures for 40-52 weeks including questionnaires, physical exams, blood and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab injections following FDA-approved psoriasis treatment regimen.

PsoriasisCardiovascular Disease

University of Pennsylvania81 participantsStarted Apr 2013

Sacramento, California, United States • Denver, Colorado, United States • Bethesda, Maryland, United States +6 more locations

COMPLETEDPhase 1/2< 1 mile

Phase 1 and 2 Study of PX-866 and Cetuximab

NCT01252628

The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment. In the Phase 1 part of the study, the dose of PX-866 to be given in combination with cetuximab will be determined in patients with incurable metastatic CRC or incurable progressive, recurrent or metastatic SCCHN. The Phase 2 part of the study is a randomized evaluation of the antitumor activity and safety of PX-866 in combination with cetuximab versus cetuximab alone in patients with either incurable metastatic CRC who have a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens or are intolerant of irinotecan (Group 1) or incurable progressive, recurrent or metastatic SCCHN (Group 2).

Incurable Metastatic Colorectal CarcinomaIncurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Cascadian Therapeutics Inc.178 participantsStarted Dec 2010

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Escondido, California, United States +37 more locations

Vascular Inflammation in Psoriasis - Extension Study

Phase 1 and 2 Study of PX-866 and Cetuximab

Find Trials by Condition in Denver

A Study in Participants With Rheumatoid Arthritis

Evaluation of Potential Allergenicity of New Wheat Varieties

Phase I Trial of Oral PX-866

Phase 1 Study of ONT-10 in Patients With Solid Tumors

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

PF-00489791 For The Treatment Of Raynaud's

Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

Behavioral & Nutritional Treatment to Help CF Preschoolers Grow

Radiosurgery or Open Surgery for Epilepsy Trial

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

The Impact of Vitamin D on Disease Activity in Crohn's Disease

A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017